Skip to main content
SpringerLink
Log in

Management of Type 2 Diabetes Mellitus

  • Chapter
  • First Online:
Atlas of Diabetes

  • 3873 Accesses

Abstract

Diabetes and its complications are a significant cause of morbidity and mortality in the USA. The prevalence of diabetes has been steadily increasing in the adult population, based on national household surveys that were conducted (see Fig. 8.1) [1, 2]. Undiagnosed diabetes and abnormal glucose tolerance are considered to have substantial clinical importance (see Fig. 8.2) [1, 3–6].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cowie CC, Rust KF, Ford ES, et al.: Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care 2009, 32:287–294.

    Google Scholar 

  2. Ong KL, Cheung BMY, Wong LYF, et al.: Prevalence, treatment, and control of diagnosed diabetes in the U.S National Health and Nutrition Examination Survey 1999–2004. Ann Epidemiol 2008, 18:222–229.

    Google Scholar 

  3. Gregg EW, Cadwell BL, Cheng YJ, et al.: Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care 2004, 27:2806–2812.

    Google Scholar 

  4. Wee CC, Hamel MB, Huang A, et al.: Obesity and undiagnosed diabetes in the U.S. Diabetes Care 2008, 31:1813–1815.

    Google Scholar 

  5. Selvin E, Coresh J, Brancati FL: The burden and treatment of diabetes in elderly individuals in the U.S. Diabetes Care 2006, 29:2415–2419.

    Google Scholar 

  6. Centers for Disease Control and Prevention: National Diabetes Fact Sheet 2007. Available at: http://www.cdc.gov/diabetes/pubs/estimates07.htm#1. Accessed March 5, 2010.

  7. American Diabetes Association Position Statement: Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl 1):S62–S67.

    Article  Google Scholar 

  8. DeFronzo RA: Banting lecture 2009. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes. Diabetes 2009, 58:773–795.

    Google Scholar 

  9. Boden G, Chen X: Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 1995, 96:1261–1268.

    Google Scholar 

  10. Groop LC, Bonadonna RC, DelPrato, S et al.: Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989, 84:205–213.

    Google Scholar 

  11. Lewis GF, Carpentier A, Vranic M, Giacca A: Resistance to insulin’s acute direct hepatic effect in suppressing steady-state glucose production in individuals with type 2 diabetes. Diabetes 1999, 48:570–576.

    Google Scholar 

  12. Shepard PR, Kahn BB: Mechanisms of disease: glucose transporters and insulin action—implications for insulin resistance and diabetes mellitus. N Engl J Med 1999, 341:248–257.

    Google Scholar 

  13. Weyer C, Tataranni PA, Bogardus C, et al.: Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2000, 24:89–94.

    Google Scholar 

  14. Kahn S: The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001, 86:4047–4058.

    Google Scholar 

  15. Weyer C, Bogardus C, Mott D, et al.: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999, 104:787–794.

    Google Scholar 

  16. Nguyen NT, Magno CP, Lane KT, et al.: Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg 2008, 207:928–934.

    Google Scholar 

  17. Hu F, Manson J, Stamfer M, et al.: Diet, lifestyle, and the risk of type 2 diabetes in women. N Engl J Med 2001, 345:790–797.

    Google Scholar 

  18. Wei M, Schweitner H, Blair S: The association between physical activity, physical fitness, and type 2 diabetes mellitus. Compr Ther 2000, 26:176–182.

    Google Scholar 

  19. American Diabetes Association: Position statement. Screening for type 2 diabetes. Diabetes Care 2004, 27(Suppl 1):S11–S14.

    Google Scholar 

  20. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009, 32:1327–1334.

    Google Scholar 

  21. National Diabetes Statistics, 2007. NIH Publication No. 08–3892. June 2008. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/.

  22. Geiss LS, Herman WH, Smith PJ: Mortality in non-insulin dependent diabetes. In Diabetes in America, edn 2. National Diabetes Data Group, Bethesda, MD: National Institute of Health; NIH pub no. 95–1468, 1995, 233–257.

    Google Scholar 

  23. Malmberg K, Yusuf S, Gerstein HC, et al.: Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000, 102:1014–1019.

    Google Scholar 

  24. Haffner SM, Lehto S, Rönnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–234.

    Google Scholar 

  25. Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest 2000, 106:453–458.

    Google Scholar 

  26. Hsueh WA, Law RE: Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med 1998, 105:4S–14S.

    Google Scholar 

  27. Adler AI, Stratton IM, Neil HA, et al.: Association of systolic blood pressure with macrovascular complications of type 2 diabetes (UKPDS: 36) BMJ 2000, 321:412–419.

    Google Scholar 

  28. Meigs JB, Mittleman MSA, Nathan DM, et al.: Hyperinsulinemia, hyperglycemia and impaired homeostasis. The Framingham Offspring Study. JAMA 2000, 283:221–228.

    Google Scholar 

  29. Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K: Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens 2001, 14:475–486.

    Google Scholar 

  30. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813–820.

    Google Scholar 

  31. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434–444.

    Google Scholar 

  32. Turner RC, Millns H, Neil HA, et al.: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316:823–828.

    Google Scholar 

  33. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977–986.

    Google Scholar 

  34. The Diabetes Complications and Control/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000, 342:381–389.

    Google Scholar 

  35. The Diabetes Control and Complications (DCCT) Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995, 47:1703–1720.

    Google Scholar 

  36. United Kingdom Prospective Diabetes Study Group: Effect of intensive blood glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998, 352:837–853.

    Google Scholar 

  37. Ohkubo Y, Kishikawa H, Araki E, et al.: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103–117.

    Google Scholar 

  38. Reichard P, Pihl M, Rosenqvist U, Sule J: Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia 1996, 39:1483–1488.

    Google Scholar 

  39. Stratton IM, Adler AI, Neil HAW, et al. for the UK Prospective Diabetes Study Group: Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405–412.

    Google Scholar 

  40. Holman RR, Paul SK, Bethel MA, et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577–1589.

    Google Scholar 

  41. Lachin JM, Genuth S, Nathan DM, et al.: DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes 2008, 57:995–1001.

    Google Scholar 

  42. Nathan DM, Cleary PA, Backlund JY, et al.: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive Diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 22:2643–2653.

    Google Scholar 

  43. The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N Engl J Med 2008, 358:2560–2572.

    Google Scholar 

  44. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559.

    Google Scholar 

  45. Duckworth W, Abraira C, Moritz T, et al. for the VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes. N Eng J Med 2009, 360:129–139.

    Google Scholar 

  46. Turnbull FM, Abraira C, Anderson RJ, et al.: Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52:2288–2298.

    Google Scholar 

  47. Skyler JS, Bergenstal R, Bonow RO, et al.: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VADT diabetes trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009, 32:187–192, Circulation 2009, 119:351–357, and J Am Coll Cardiol 2009, 53:298–304.

    Google Scholar 

  48. American Diabetes Association: Standards of medical care in diabetes—2010. Diabetes Care 2010, 33:S11–S61.

    Google Scholar 

  49. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007,13(Suppl 1):1–68.

    Google Scholar 

  50. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253–259.

    Google Scholar 

  51. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755–1762.

    Google Scholar 

  52. Collins R, Armitage J, Parish S, et al., Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005–2016.

    Google Scholar 

  53. Colhoun HM, Betteridge DJ, Durrington PN, et al., CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685–696.

    Google Scholar 

  54. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495–1504.

    Google Scholar 

  55. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive summary of the third report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001, 285:2486–2497.

    Google Scholar 

  56. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393.

    Google Scholar 

  57. Gaede P, Lund-Andersen H, Parving HH, et al.: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580–591.

    Google Scholar 

  58. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26:3080–3086.

    Google Scholar 

  59. Holman RR, Thorne KI, Farmer AJ, et al., 4-T Study Group: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007, 357:1716–1730.

    Google Scholar 

  60. Holman RR, Farmer AJ, Davies MJ, et al., 4-T Study Group: Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009, 361:1736–1747.

    Google Scholar 

  61. Drucker DJ: Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003, 26:2929–2940.

    Google Scholar 

  62. Palalau AI, Tahrani AA, Piya MK, Barnett AH: DPP-4 inhibitors in clinical practice. Postgrad Med 2009, 121:70–100.

    Google Scholar 

  63. Kendall DM, Cuddihy RM, Bergenstal RM: Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med 2009, 122(Suppl 6):S37–S50.

    Google Scholar 

  64. Lovshin JA, Drucker DJ: Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5:262–269.

    Google Scholar 

  65. Chia CW, Egan JM: Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 2008, 93:3703–3716.

    Google Scholar 

  66. Fonseca VA, Handelsman Y, Staels B: Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab 2010, 12:384–392.

    Google Scholar 

  67. Pijl H, Ohasi H, Marsuda M, et al.: Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000, 23:1154–1161.

    Google Scholar 

  68. Gaziano JM, Cincotta AH, O’Connor CM, et al.: Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010, 33:1503–1508.

    Google Scholar 

  69. Edelman S, Maier H, Wilhelm K: Pramlintide in the treatment of diabetes mellitus. BioDrugs 2008, 22:375–386.

    Google Scholar 

  70. Riddle M, Pencek R, Charenkavanich S, et al.: Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care 2009, 32:1577–1582.

    Google Scholar 

  71. Nathan DM, Buse JB, Davidson MB, et al.: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193–203.

    Google Scholar 

  72. Rodbard HW, Jellinger PS, Davidson JA, et al.: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540–559.

    Google Scholar 

  73. International Diabetes Federation: Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation; 2005. Available at http://www.idf.org/node/1285?unode=B7462CCB-3A4C-472C-80E4-710074D74AD3.

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Miami VA Healthcare System, School of Medicine, University of Miami, Miami, FL, USA

    Jennifer B. Marks MD (Professor of Medicine)

Authors
  1. Jennifer B. Marks MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer B. Marks MD .

Editor information

Editors and Affiliations

  1. Division of Endocrinology,, Diabetes & Metabolism, University of Miami, Miami, 33136, Florida, USA

    Jay Skyler

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Marks, J.B. (2012). Management of Type 2 Diabetes Mellitus. In: Skyler, J. (eds) Atlas of Diabetes. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-1028-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-1028-7_8

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-1027-0

  • Online ISBN: 978-1-4614-1028-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation